In many ways, the collaborative research movement grew up around Vaccines. Thanks in large part to HIV advocacy, out-of date research models that were competitive and closed-door are increasingly yielding to more transparent and collaborative research and development efforts—in both the HIV and COVID-19 responses.

Building on big science partnerships, data sharing and collaboration pioneered over the last 15 years of Vaccines research and development, global initiatives are marshalling the talents, experiences and resources of key stakeholders. And just as HIV laid the foundation for more effective partnerships in research, lessons from the COVID-19 experience can also inspire greater collaboration and broader involvement by a range of players in the vaccines research effort.

Excerpted from 5 “P”s to Watch.

Topics:

Accelerating Product Innovation